The Russian Ministry of Health has granted permission to the Gamaleya Center to conduct phase I-II clinical trials of a COVID-19 vaccine based on VLP virus-like particles. This is reported by TASS with reference to the state register of the department.

This drug can be tested by volunteers over 18 years of age.

The Phase I/II study is planned to be conducted in participants aged 18–55 years.

Volunteers will have to "evaluate the tolerability, safety and immunogenicity of the vaccine."

A new drug designed to prevent coronavirus infection will contain particles similar to SARS-CoV-2.

At the moment, the timing of clinical trials of a new coronavirus vaccine is not known.

Earlier, the Head of the Gamaleya Research Center for Epidemiology and Microbiology, Alexander Gintsburg, revealed the details of the nasal vaccine trial. The nasal vaccine "Sputnik V" differs from the original one not only in the form of introduction into the body, but also in the emerging immunity.

bbabo.Net